1
|
Mahar PS, Monis MD, Memon AS, Azam M. Bilateral Acute Posterior Multifocal Placoid Pigment Epitheliopathy With Bacillary Layer Detachment Following Sinopharm COVID-19 Vaccination: A Case Report. Cureus 2024; 16:e55369. [PMID: 38562362 PMCID: PMC10982682 DOI: 10.7759/cureus.55369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/29/2024] [Indexed: 04/04/2024] Open
Abstract
Various ocular manifestations associated with COVID-19 and vaccines, affecting both the anterior and posterior segments of the eye have been documented in the literature. In this report, we present the case of a 25-year-old male who complained of sudden-onset blurred vision and metamorphopsia in both eyes one day after receiving the second dose of the Sinopharm COVID-19 vaccine. The visual loss was painless, with no reported flashes or floaters. The patient had no significant medical or surgical history, no history of trauma, and no drug intake. Upon ocular examination, the best-corrected visual acuity was 6/60 (Snellen chart) in both eyes. The anterior segments appeared unremarkable, while fundoscopy revealed multiple yellowish-white subretinal lesions at the posterior pole of both eyes. Spectral domain optical coherence tomography (SD-OCT) confirmed the presence of subretinal fluid (SRF) with neurosensory detachment in each eye, along with bacillary layer detachment (BALAD). There were no signs of inflammation in the vitreous cavity. A diagnosis of acute posterior multifocal plaque pigment epitheliopathy (APMPPE) was established. The patient was prescribed nepafenac 0.1% drops to be instilled three times a day in both eyes and was advised to return for a follow-up examination in two weeks. At the follow-up visit, the patient's vision had improved to 6/9 in the right eye and 6/6 in the left eye, with most of the SRF absorbed. Unilateral APMPPE with BALAD has been mentioned in the literature following various COVID-19 vaccinations, but, to the best of our knowledge, this is the first case report where bilateral APMPPE with BALAD is reported. This case emphasizes the importance of a thorough eye examination for individuals experiencing ocular symptoms after receiving the COVID-19 vaccine.
Collapse
Affiliation(s)
- P Salim Mahar
- Ophthalmology, Aga Khan University Hospital, Karachi, PAK
- Ophthalmology, Isra Postgraduate Institute of Ophthalmology, Karachi, PAK
| | | | | | - Muhammad Azam
- Ophthalmology, Isra Postgraduate Institute of Ophthalmology, Karachi, PAK
| |
Collapse
|
2
|
Haider T, Abidi SRZ, Fatima M, Zafar A, Siddiqui RQU, Khan W, Saeed T, Anwar A, Hashmi AA. The Prevalence of Side Effects of Sinopharm COVID-19 Vaccine: An Experience From Pakistan. Cureus 2023; 15:e38180. [PMID: 37252607 PMCID: PMC10220323 DOI: 10.7759/cureus.38180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/26/2023] [Indexed: 05/31/2023] Open
Abstract
Introduction Vaccination for coronavirus disease 2019 (COVID-19) helps develop protective immunity against COVID-19 without experiencing potentially severe illness. Many vaccines are used worldwide, but there is little data on the efficacy and side effects of the Sinopharm vaccine. Therefore, this study aimed to investigate the reported adverse effects of the Sinopharm vaccine among participants. Methods This prospective cross-sectional study was conducted in multiple hospitals in Karachi, Pakistan. The study was eight months, from April 1, 2022, to November 30, 2022. A total of 600 participants who gave informed consent and had received their first and second doses of the Sinopharm vaccine were included in the study. As hypertension and diabetes mellitus (DM) are common prevalent conditions in our population, the duration of DM and hypertension were documented as means and standard deviations apart from age, height, and weight. Side effects of the Sinopharm vaccine were reported as frequencies and percentages. Results The study findings showed that out of 600 participants, 376 (62.7%) were males and 224 (37.3%) were females; their mean age was 42.79±14.44 years. Among them, 130 (21.7%) had hypertension, and 138 (23.0%) had DM. All participants received the Sinopharm vaccine. Fever was the most frequently reported adverse effect following the first dose of the Sinopharm vaccine in 308 (51.3% of participants), followed by burning at the injection site in 244 (40.7% of participants) and pain at the injection site in 228 (38.0% of participants). Following the second dose of the Sinopharm vaccine, fever was the most frequently reported side effect in 254 (42.3%) participants, followed by pain at the injection site in 236 (39.5%) participants and burning at the site of injection in 210 (35.0%) participants. Moreover, joint pain in 194 (32.3%), shortness of breath in 170 (28.3%), swelling of glands in 168 (28.0%), chest pain in 164 (27.3%), and muscle pain were reported by 140 (23.3%) participants. The level of satisfaction showed that the majority of the participants, 334 (55.7%), were satisfied, 132 (22.0%) were very satisfied with their vaccination, and only 12 (2.0%) were dissatisfied. Conclusion This study concluded that fever was the most frequent side effect after both doses of the Sinopharm vaccine. Pain and burning at the injection site and joint pain were among the other common side effects reported by most participants. The Sinopharm COVID-19 vaccine had mild, predictable, and non-life-threatening side effects after the first and second doses.
Collapse
Affiliation(s)
- Taimur Haider
- Pediatrics, District Headquarter Hospital, Jhang, PAK
| | | | - Mehwish Fatima
- Biochemistry, Jinnah Sindh Medical University, Karachi, PAK
| | - Aimen Zafar
- Anaesthesiology, Baqai Medical University, Karachi, PAK
| | | | - Wadan Khan
- Internal Medicine, Bolan Medical Complex Hospital, Quetta, PAK
| | - Tazeen Saeed
- Internal Medicine, Karachi Medical and Dental College, Karachi, PAK
| | - Adnan Anwar
- Physiology, Hamdard College of Medicine and Dentistry, Karachi, PAK
| | - Atif A Hashmi
- Pathology, Liaquat National Hospital and Medical College, Karachi, PAK
| |
Collapse
|
3
|
Aliakbarian M, Khodashahi R, Sabbagh MG, Rezayat KA, Khodashahi M, Khaleghi E, Moghaddam MD, Razmkhah B, Nazar MN, Sheikhi N. Complications and Efficacy of Sinopharm Vaccine among Liver and Kidney Transplantation. Curr Drug Saf 2023; 18:15-22. [PMID: 35249504 DOI: 10.2174/1574886317666220304122420] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2021] [Revised: 01/08/2022] [Accepted: 02/16/2022] [Indexed: 02/08/2023]
Abstract
BACKGROUND There are various vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, vaccination may lead to some complications. OBJECTIVE This study aimed to investigate the complications of transplant recipients who received the Sinopharm COVID-19 vaccine. METHODS This was a retrospective cross-sectional study conducted among 667 transplant recipients (211 liver transplant recipients and 456 kidney transplant recipients) who received the Sinopharm COVID-19 vaccine from March to August 2021 and had medical records in Montaserieh Hospital, affiliated to Mashhad University of Medical Sciences, Mashhad, Iran. The demographic and clinical information, as well as patient's symptoms after each dose of the vaccine, were recorded. RESULTS Only 16.8% and 13.7% of the patients experienced some symptoms following the first and second doses of the Sinopharm vaccine, respectively. No significant difference was observed between patients younger than 50 years and those aged 50 years and over in terms of the complication rate of the Sinopharm vaccine (P>0.005). Vaccine failure was reported in 10% of the cases; however, the mortality rate due to infection with the Delta variant of COVID-19 in this population was reported to be 0.7%. CONCLUSION Based on the obtained results, adverse reactions of the Sinopharm COVID-19 vaccine are generally mild, predictable, and non-life-threatening both in the first and second doses. Vaccine failure was reported in 10% of the cases; however, mortality due to infection with the Delta variant of COVID-19 was reported in less than 1% of the cases.
Collapse
Affiliation(s)
- Mohsen Aliakbarian
- Hepatopancreatobiliary & Transplant Surgery, Mashhad Transplant Research Center, Montaserieh Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.,Surgical Oncology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Rozita Khodashahi
- ID Specialist, Fellowship in IC host & transplant, Clinical Research Development Unit, Imam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.,Mashhad Transplant Research Center, Montaserieh Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.,Department of Infectious Diseases and Tropical Medicine, Faculty of Medicine, Mashhad University of Sciences, Mashhad, Iran
| | - Mahin Ghorban Sabbagh
- Kidney Transplantation Complications Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Kambiz Akhavan Rezayat
- Department of Gastroenterology and Hepatology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Mandana Khodashahi
- Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Ebrahim Khaleghi
- Organ Procurement & Transplant Center, Montaserieh Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Maliheh Dadgar Moghaddam
- Community Medical Department, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Baran Razmkhah
- Student Research committee, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Mahdi Nik Nazar
- Student Research committee, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Nadia Sheikhi
- Student Research committee, Mashhad University of Medical Sciences, Mashhad, Iran
| |
Collapse
|
4
|
Fakhari MS, Poorsaadat L, Mahmoodiyeh B. Guillain-Barré syndrome following COVID-19 vaccine: A case report. Clin Case Rep 2022; 10:e6451. [PMID: 36254149 PMCID: PMC9558586 DOI: 10.1002/ccr3.6451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2022] [Revised: 09/26/2022] [Accepted: 09/30/2022] [Indexed: 11/11/2022] Open
Abstract
Coronavirus disease is a viral infection affecting different organs with various morbidities and mortality. Vaccines are used to control the disease. COVID‐19 vaccines have brought many benefits but their adverse effects should not be ignored. Here, we report a case of Guillain–Barré Syndrome Following Sinopharm COVID‐19 Vaccine. Though vaccination against COVID‐19 have brought many benefits, one should consider various adverse effects of the vaccines, as they might result in severe reactions—like Guillain–Barré Syndrome.
Collapse
Affiliation(s)
| | - Leila Poorsaadat
- Department of Neurology, School of MedicineArak University of Medical SciencesArakIran
| | - Behnam Mahmoodiyeh
- Department of Anesthesiology, School of MedicineArak University of Medical SciencesArakIran
| |
Collapse
|